Patrick Blaney
Has grant
Senior Bioinformatics Programmer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Role of disadvantage, mutographs and T cell immunity on MGUS in African Americans
Open Date: 2025-01-01
Close Date: 2030-01-01
Grant: Close
Using mutographs to define the molecular landscape and cell of origin of Waldenstrom’s Macroglobulinemia
Open Date: 2023-01-01
Close Date: 2025-01-01
Grant: Close
Polyethnic-1000
Open Date: 2021-01-01
Close Date:
Grant: Close
Mutographs differentiating the racial and temporal incidence of Multiple Myeloma
Open Date: 2021-01-01
Close Date: 2026-01-01
Articles (61)
The H3K36me2 methyltransferase NSD2 is deleted in Wolf-Hirschhorn syndrome and aberrantly expressed in 10-15% of multiple myeloma (MM) due to a t(4;14) translocation. Although NSD2 is thought to be a primary driver in MM, the exact molecular mechanisms by which it regulates transcription remain unclear. We applied the dTAG system to acutely degrade NSD2 and used this, in combination with time-resolved SLAM-seq, to identify 307 transcriptional targets of NSD2. Reconstitution with either wild-type NSD2 or a catalytically inactive mutant (NSD2Y1179A) showed that NSD2's transcriptional effects are almost exclusively dependent on its SET domain activity. Mechanistically, H3K36me2 deposition by NSD2 antagonizes H3K27me3 levels, and treatment with two distinct PRC2 inhibitors demonstrated that approximately half of NSD2 target genes are regulated in an H3K27me3-dependent manner. CUT&Tag analysis showed that upon NSD2 depletion there was an increase in H3K27me3 that occurred at genome-wide intergenic regions, rather than at the promoters or gene bodies of NSD2 target genes. These data suggest that NSD2, via H3K36me2, antagonizes H3K27me3 deposition likely at distal regulatory elements including enhancers, creating a chromatin landscape favorable for target gene transcription. Importantly, NSD2 target genes were enriched for key oncogenic pathways, and 24 transcription factors implicated in neurodevelopment and acute leukemia, consistent with its role in Wolf-Hirschhorn syndrome and MM. Eight of these transcription factors are known oncogenic drivers in acute leukemia or MM, highlighting a novel molecular mechanism for NSD2's role in t(4;14) MM.
Year:
2026
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Year:
2026
Year:
2026
Year:
2026
Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that a preferred alternative to self-described race is using ancestry-informative markers (AIMs) that can be classified into ancestral components and used to estimate their similarity to those of known populations to identify continental groups. However, real-world genomic data can present challenges, including limited availability of germline DNA, a small number of AIMs for each sample, and the use of different variant calling software, limiting the application of existing solutions. Results Here, we describe a novel supervised machine-learning tool AncestryGeni, which infers genetic ancestry for samples with even a hundred markers and is applicable to any genomic data, including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) data. Applying AncestryGeni to a real-world genomic dataset obtained from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, we show that it is more accurate than the commonly used FastNGSadmix when using nonstandard genomic material. We also demonstrate that when using AncestryGeni, the tumor-derived sequence obtained from WES and RNA-Seq can be a robust data source to accurately estimate an individual’s genetic similarity to a continental group. Availability and implementation AncestryGeni pipeline is available at https://github.com/eelhaik/AncestryGeni/tree/main.
Year:
2025
Year:
2025
We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.
Year:
2025
Background The bone marrow (BM) niche contains non-hematopoietic elements including mesenchymal stromal cells (MSC) and bone marrow endothelial cells (BMEC) which provide mechanical support, and control hematopoietic cell growth and differentiation. Although it is known that multiple myeloma (MM) cells interact closely with the BM microenvironment, little is known about the impact of MM on non-hematopoietic niche-forming cells. Methods To address the role of the niche in MM pathogenesis, we utilized the 5TGM1 murine model. During the asymptomatic precursor stage of the model, we isolated the rare non-hematopoietic cells and performed single cell RNA sequencing. Using in-silico methods we characterized the individual cellular components of the niche, their relative abundance and differentiation state before and after exposure to MM cells as well as their intercellular interactions. Results MM engraftment increased the abundance of MSC-lineage cells, BMECs and enhanced endothelial to mesenchymal transition. An inflammatory and oxidative stress signal was identified together with polarization of MSC differentiation away from osteocyte formation towards adipocytes which provide growth factors that are known to support MM expansion. BMEC differentiation was polarized towards sinusoidal endothelial cells with a pro-angiogenic/pro-inflammatory phenotype. Conclusions MM cells impact the BM niche by generating a pro-inflammatory microenvironment with MSC differentiation being changed to generate cell subsets that favor MM growth and survival. In order to induce remission and improve long-term outcome for MM patients these inflammatory and oxidative stress signals need to be reduced and normal niche differentiation trajectories restored.
Year:
2025
Chromatin state of varying deleted regions. There is a greater variability in terms of chromatin composition of the lost regions in comparision to the region of gain. The D1 region had identical an A-compartment percentage (56%) across all samples and reflected loss of significant subtelomeric region, including TNFRSF4. The D2 region was consistent across all samples (range 96-100% A-compartment) with the exception of KMS11 (47%), however this switch to a B-compartment occurred in a gene-sparse region. The D3 region encompasses the tumour suppressor genes CDKN2C and FAF1 and had similar active chromatin profiles (range 44-77%) except in RPMI8226 (0%). The D4 and D5 regions lie completely (100%) and near completely (>87%) in inactive compartments. Interestingly, the small A-compartments in D5 across U266 and RPMI8226 correspond to the tumour suppressor FUBP1. The D6 region showed conserved A-compartment across the samples specifically at the RPL5 and MTF2 loci while EVI5 and GFI1 showed switching from B-A across the differentiation stages. The D7 region, focused on TENT5C lies within an A-compartment across all samples except for KMS11, NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.
Year:
2025
Chromatin state of different SV regions. The CT1 region at 1p36.11-1p34.3 is comprised of greater than 74% A-compartment (range 74-100%); CT2 at 1p33-1p32.3 comprises both inactive (range 35-59%) and active chromatin (range 41-65%) and, CT3 at 1p13.3-1p12, overlaps with TI1, had greater variability with 86% A-compartment in U266 while only 1% in KMS11. TI1 region predominantly laid in B-compartment (range 63-73%) and TI2 lay in an almost entirely active compartment (range 91-100%). NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (27)
Marc Braunstein
-
Behnam Nabet
Assistant Professor
Fred Hutchinson Cancer Research Center
Esteban Braggio
Assistant Professor
Mayo Clinic
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
Xiaoyi Chen
Assistant professor
Rutgers Cancer Institute of New Jersey
David Kaminetzky, M.D.
Assistant Professor (Clinical) of Medicine
NYU School of Medicine
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Jill Corre
-
Arnaldo Arbini
Associate Professor (Clinical) of Pathology
NYU School of Medicine
Brian Walker
Professor
University of Miami
Aristotelis Tsirigos
Associate Professor (Research) of Pathology
NYU School of Medicine
Giancarlo Castellano
Fondazione IRCCS Istituto Nazionale dei Tumori
Michael Bauer
Associate Professor
University of Arkansas for Medical Sciences
David G. Coffey
Assistant Professor
University of Miami School of Medicine
Bachisio Ziccheddu
Sylvester Comprehensive Cancer Center, University of Miami
Benedetto Bruno
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Lukas John
Deutsches Krebsforschungszentrum
Irene Ghobrial
Professor of Medicine
Dana-Farber Cancer Institute
Niccolò Bolli
Associate Professor
University of Milan
Saad Usmani
Chief Attending
Memorial Sloan Kettering Cancer Center
Florence Nguyen-Khac
Sorbonne Université
Gad Getz
Broad Institute
Gaurav Varma
Assistant Professor of Medicine
Weill Cornell Medicine
Dickran Kazandjian
University of Miami
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Eran Elhaik
Associate Professor
Lund University
Juan-José Garcés
Research Scholar
Sloan Kettering Institute
Make your next move.
Prepare your application
Review drafts before you send them.